SKC's Orphan Drug and Gene Therapy Seminars in Cambridge, MA (USA) in September

Mon, 2018 / 09 / 03
The requirements for market access of orphan drugs and gene therapies in Europe are considerably different from the ones in the US: The European market authorization conducted by the EMA is only the starting point for different reimbursement processes, governed by national HTA-bodies, payer associations and health policy makers in separate European countries. Hence an early strategical analysis and approach becomes crucial for the successful market access of innovative products like orphan drugs or gene therapies.

We would like to invite you to our exclusive seminars:

Strategic Challenges of Orphan Drug Market Access in Europe

, 2018, 2:30 pm to 4:30 pm
At the Harvard Faculty Club in Cambridge, MA, USA

The seminar consists of a keynote and an interactive Q&A session that will inter alia address:

  • Ten steps of sound and professional market access in Europe

  • Key success factors for pricing and reimbursement in Europe




Successful Market Access for Gene Therapies – Strategic Solutions


On September 24th, 2018, 5:30 pm to 7:30 pm
At the Harvard Faculty Club in Cambridge, MA, USA

The seminar consists of a keynote and an interactive Q&A session that will inter alia address:

  • Challenges and regulatory requirements for the market access of gene therapies

  • Key learnings for the approval and reimbursement process of gene therapies


Register now for free
Do you want to take part? Please click on the buttons above to register for our free seminars (limited capacity). For any questions please call +49 511 64 68 140 or send an email to contact@skc-beratung.de.

SKC is the leading and most reputable strategy consultancy in the German health care sector. We have been supporting pharmaceutical companies for many years by making orphan drugs for German and European patients available. As experts for gene therapies we are in constant exchange with all relevant stakeholders.

Our recent corresponding white papers provide further insights and will be distributed at the meeting:

Host: Prof. Matthias P. Schönermark, M.D., Ph.D., managing director of SKC, is a trained head & neck surgeon with a Ph.D. in molecular oncology. He was appointed as Professor of Health Care Management at Hannover Medical School in 2001. In his function as managing partner of SKC, he is a permanent consultant to numerous leadership personalities of international health insurance and provider organizations, as well as of pharmaceutical and medtech companies on strategic management, innovation management and change management issues.
to the top